Healthcare Industry News:  Advanced Circulatory 

Devices Venture Capital

 News Release - July 31, 2013

Advanced Circulatory Closes $2 Million Bridge Financing

MINNEAPOLIS--(Healthcare Sales & Marketing Network)--Advanced Circulatory, makers of multiple medical devices and the pioneer of Perfusion on DemandTM (POD) therapy, announced today that the company has raised $2 million in bridge financing. The company will use the bridge funds to support the continued global commercialization of its ResQPOD® and ResQGARD® Impedance Threshold Devices (ITDs) as well as the launch and commercialization of its ResQCPR® System, which is currently pending regulatory approvals.

The ResQPOD and ResQGARD ITDs deliver POD therapy - a therapy with far reaching implications for multiple medical conditions - by enhancing perfusion non-invasively. The therapy increases circulation, protecting the heart, brain and other vital organs when blood flow is compromised, giving rescuers, clinicians and caregivers the potential to return patients to a full life after critical medical emergencies. When used in patients in shock, studies have shown that the ITD increases blood pressure up to 30%.1-3 In addition, studies have shown the use of ITDs during CPR increases the rate of neurologically intact survival of cardiac arrest by 25% or more when compared to conventional CPR alone.4-8

The company’s ResQCPR® System, which is currently in review with the US FDA, combines the ResQPOD ITD technology with the ResQPUMP® active compression/decompression CPR (ACD-CPR) device to optimize performance of CPR. This synergistic combination of the ITD and the ACD-CPR pump enhances the intrathoracic vacuum even further and provides near-normal circulation during cardiac arrest.9 A recent randomized control trial published in Lancet10 showed that use of these devices together results in a 53% increase in neurologically intact survival of cardiac arrest.

Mike Black, Advanced Circulatory’s CEO and Director, commented, “Our Perfusion on Demand therapy has the potential to have a global impact on patient care, and this financing round will help us push education and adoption of our life-saving therapies.”

Advanced Circulatory manufactures and markets the ResQPOD® and the ResQGARD® Impedance Threshold Devices in over 25 countries worldwide.

1. Smith SW, Parquette B, Lindstrom D, et al. An impedance threshold device increases blood pressure in hypotensive patients. J Emerg Med 2011; 41(5):549-558

2. Metzger A, Rees J, McKnite S, et al. Augmentation of negative intrathoracic pressure improves hemodynamics without popping the clot: a randomized study comparing an impedance threshold device versus saline to treat severe hemorrhage through permissive hypotension in a spontaneously breathing porcine model. Prehosp Emerg Care 2012; 16(1): 174.

3. Convertino VA, Parquette B, Zeihr J, et al. Use of respiratory impedance in prehospital care of hypotensive patients associated with hemorrhage and trauma: a case series. J Trauma Acute Surg 2012; 73(2):S54-S59.

4. Lick CJ, Aufderheide TP, Niskanen RA, et al. Take Heart America: a comprehensive, community-wide, systems-based approach to the treatment of cardiac arrest. Crit Care Med. 2011;39(1):26-33.

5. Aufderheide TP, Alexander C, Lick C, et al. From laboratory science to six emergency medical service systems: new understanding of the physiology of cardiopulmonary resuscitation increases survival rates after cardiac arrest. Crit Care Med 2008; 36(11):S397-S404.

6. Aufderheide TP, Yannopoulos D, Lick CJ, et al. Implementing the 2005 American Heart Association guidelines improves outcomes after out-of-hospital cardiac arrest. Heart Rhythm. 2010;9(10):1357-1364.

7. Thigpen K, Davis SP, Basol R, et al. Implementing the 2005 American Heart Association guidelines, including use of an impedance threshold device, improves hospital discharge rate after in-hospital cardiac arrest. Respir Care. 2010;55(8):1014-1019.

8. Hinchey PR, Myers JB, Lewis R, et al, for the Capitol County Research Consortium. Improved out-of-hospital cardiac arrest survival after the sequential implementation of the 2005 AHA guidelines for compressions, ventilations and induced hypothermia: the Wake County experience. Ann Emerg Med. 2010;56(4):358-361.

9. Plaisance P, Lurie KG, Payen D. Inspiratory impedance during active compression decompression cardiopulmonary resuscitation. Circulation 2000; 101:989-994.

10. Aufderheide TP, Frascone RJ, Wayne MA, et al. Standard cardiopulmonary resuscitation versus active compression-decompression cardiopulmonary resuscitation with augmentation of negative intrathoracic pressure for out-of-hospital cardiac arrest: a randomised trial. Lancet. (ResQTRIAL) 2011;377(9762):301-311.

Additional studies available upon request. The generally cleared indication for the ResQPOD available for sale in the United States (US) is for a temporary increase in blood circulation during emergency care, hospital, clinic, and home use. Research is ongoing in the US to evaluate the long-term benefit of the ResQPOD for indications related to patients suffering from cardiac arrest. The studies referenced here are not intended to imply specific outcomes-based claims not yet cleared by the US FDA.

Source: Advanced Circulatory

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.